Taryn E. Gillies
Research Subjects
Taryn E. Gillies has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- John G. Albeck
University of California, Davis
3 shared publications Michael Pargett
Department of Molecular and Cellular Biology University of California Davis CA USA
3 shared publicationsAlana Killeen
Nautilus Biotechnology, Inc., San Carlos, CA
1 shared publicationAlex E. Davies
Department of Molecular and Cellular Biology, University of California, Davis, CA 95616, USA; Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
1 shared publicationBreanne Sparta
University of California, Davis
1 shared publicationCarolyn K Teragawa
Department of Molecular and Cellular Biology University of California Davis CA USA
1 shared publication
Latest Publications
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , LB225
Abstract LB225: Toward comprehensive, single-molecule proteomics: Protein identification by short-epitope mapping
Protein Identification by Short-epitope Mapping (PrISM) is a novel proteomics method with the goal of comprehensive proteome quantification at single-molecule sensitivity. In this work, we present computational modeling demonstrating the feasibility of this goal and experimental application of the approach leveraging single-molecule protein measurements to identify a small number of model proteins. The implementation of PrISM as presented works by acquiring sequential affinity reagent binding measurements on single protein molecules. Counterintuitively, using affinity reagents with “poor” specificity (i.e. cross-reacting to many proteins) enables identification of tens of thousands of proteins with only hundreds of affinity reagents. To experimentally demonstrate PrISM, we use a small number of affinity reagents to quantify a larger number of proteins. In simulations, PrISM is able to identify more than 98% of proteins in human, mouse, yeast, and E. coli using 300 affinity reagents targeting short trimer epitopes. PrISM is robust to experimental confounders including non-specific binding and noisy, incomplete, or inaccurate estimation of affinity reagent to protein binding characteristics. Simulations of the approach with a chip containing 10 billion protein molecules measured in parallel show a dynamic range of detection of up to 9.5 and 11.5 orders of magnitude for HeLa cells and plasma, respectively. Using such a chip, the PrISM method can identify and quantify over 90% of the human proteome in a single experiment, potentially revolutionizing biomarker discovery and cancer research. Citation Format: Jarrett D. Egertson, Cassandra Stawicki, Taryn E. Gillies, James H. Joly, Noah Steiner, Kevin Cardenas, Jonathan B. Leano, Kevin Chen, Sophie Watts, Hunter B. Boyce, Dan DiPasquo, Alana Killeen, Vadim Lobanov, Greg Kapp, Sujal Patel, Parag Mallick. Toward comprehensive, single-molecule proteomics: Protein identification by short-epitope mapping [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB225.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , LB225
Open AccessAbstract LB225: Toward comprehensive, single-molecule proteomics: Protein identification by short-epitope mapping
Protein Identification by Short-epitope Mapping (PrISM) is a novel proteomics method with the goal of comprehensive proteome quantification at single-molecule sensitivity. In this work, we present computational modeling demonstrating the feasibility of this goal and experimental application of the approach leveraging single-molecule protein measurements to identify a small number of model proteins. The implementation of PrISM as presented works by acquiring sequential affinity reagent binding measurements on single protein molecules. Counterintuitively, using affinity reagents with “poor” specificity (i.e. cross-reacting to many proteins) enables identification of tens of thousands of proteins with only hundreds of affinity reagents. To experimentally demonstrate PrISM, we use a small number of affinity reagents to quantify a larger number of proteins. In simulations, PrISM is able to identify more than 98% of proteins in human, mouse, yeast, and E. coli using 300 affinity reagents targeting short trimer epitopes. PrISM is robust to experimental confounders including non-specific binding and noisy, incomplete, or inaccurate estimation of affinity reagent to protein binding characteristics. Simulations of the approach with a chip containing 10 billion protein molecules measured in parallel show a dynamic range of detection of up to 9.5 and 11.5 orders of magnitude for HeLa cells and plasma, respectively. Using such a chip, the PrISM method can identify and quantify over 90% of the human proteome in a single experiment, potentially revolutionizing biomarker discovery and cancer research. Citation Format: Jarrett D. Egertson, Cassandra Stawicki, Taryn E. Gillies, James H. Joly, Noah Steiner, Kevin Cardenas, Jonathan B. Leano, Kevin Chen, Sophie Watts, Hunter B. Boyce, Dan DiPasquo, Alana Killeen, Vadim Lobanov, Greg Kapp, Sujal Patel, Parag Mallick. Toward comprehensive, single-molecule proteomics: Protein identification by short-epitope mapping [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB225.
- Open Access
- 1 October 2020
- Published by Springer Nature in Molecular Systems Biology
- Vol. 16 (10)
Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
Activating mutations in RAS are present in ~ 30% of human tumors, and the resulting aberrations in ERK/MAPK signaling play a central role in oncogenesis. However, the form of these signaling changes is uncertain, with activating RAS mutants linked to both increased and decreased ERK activation in vivo . Rationally targeting the kinase activity of this pathway requires clarification of the quantitative effects of RAS mutations. Here, we use live‐cell imaging in cells expressing only one RAS isoform to quantify ERK activity with a new level of accuracy. We find that despite large differences in their biochemical activity, mutant KRAS isoforms within cells have similar ranges of ERK output. We identify roles for pathway‐level effects, including variation in feedback strength and feedforward modulation of phosphatase activity, that act to rescale pathway sensitivity, ultimately resisting changes in the dynamic range of ERK activity while preserving responsiveness to growth factor stimuli. Our results reconcile seemingly inconsistent reports within the literature and imply that the signaling changes induced by RAS mutations early in oncogenesis are subtle.
- 1 October 2020
- Published by Springer Nature in Molecular Systems Biology
- Vol. 16 (10)
Open AccessOncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
Activating mutations in RAS are present in ~ 30% of human tumors, and the resulting aberrations in ERK/MAPK signaling play a central role in oncogenesis. However, the form of these signaling changes is uncertain, with activating RAS mutants linked to both increased and decreased ERK activation in vivo . Rationally targeting the kinase activity of this pathway requires clarification of the quantitative effects of RAS mutations. Here, we use live‐cell imaging in cells expressing only one RAS isoform to quantify ERK activity with a new level of accuracy. We find that despite large differences in their biochemical activity, mutant KRAS isoforms within cells have similar ranges of ERK output. We identify roles for pathway‐level effects, including variation in feedback strength and feedforward modulation of phosphatase activity, that act to rescale pathway sensitivity, ultimately resisting changes in the dynamic range of ERK activity while preserving responsiveness to growth factor stimuli. Our results reconcile seemingly inconsistent reports within the literature and imply that the signaling changes induced by RAS mutations early in oncogenesis are subtle.
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6502) , 390-+
Simultaneous cross-evaluation of heterogeneous E. coli datasets via mechanistic simulation
Testing biochemical data by simulation: Can a bacterial cell model vet large datasets from disparate sources? Macklin et al. explored whether a comprehensive mathematical model can be used to verify or find conflicts in massive amounts of data that have been reported for the bacterium Escherichia coli , produced in thousands of papers from hundreds of labs. Although most data were consistent, there were data that could not accommodate known biological results, such as insufficient output of RNA polymerases and ribosomes to produce measured cell-doubling times. Other analyses showed that for some essential proteins, no RNA may be transcribed or translated in a cell's lifetime, but viability can be maintained without certain enzymes through a pool of stable metabolites produced earlier. Science , this issue p. eaav3751
- 24 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 369 (6502) , 390-+
Simultaneous cross-evaluation of heterogeneous E. coli datasets via mechanistic simulation
Testing biochemical data by simulation: Can a bacterial cell model vet large datasets from disparate sources? Macklin et al. explored whether a comprehensive mathematical model can be used to verify or find conflicts in massive amounts of data that have been reported for the bacterium Escherichia coli , produced in thousands of papers from hundreds of labs. Although most data were consistent, there were data that could not accommodate known biological results, such as insufficient output of RNA polymerases and ribosomes to produce measured cell-doubling times. Other analyses showed that for some essential proteins, no RNA may be transcribed or translated in a cell's lifetime, but viability can be maintained without certain enzymes through a pool of stable metabolites produced earlier. Science , this issue p. eaav3751
- Open Access
- 1 November 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (47) , 17735-17757
Neuronal ER–plasma membrane junctions organized by Kv2–VAP pairing recruit Nir proteins and affect phosphoinositide homeostasis
- 1 November 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (47) , 17735-17757
Open AccessNeuronal ER–plasma membrane junctions organized by Kv2–VAP pairing recruit Nir proteins and affect phosphoinositide homeostasis
- 1 December 2017
- Published by Elsevier in Cell Systems
- Vol. 5 (6) , 549-563.e5
Linear Integration of ERK Activity Predominates over Persistence Detection in Fra-1 Regulation
- 1 December 2017
- Published by Elsevier in Cell Systems
- Vol. 5 (6) , 549-563.e5
Linear Integration of ERK Activity Predominates over Persistence Detection in Fra-1 Regulation
- 21 July 2017
- Published by Springer Nature
- Vol. 1636, 35-59
Single-Cell Imaging of ERK Signaling Using Fluorescent Biosensors
Single-cell analysis of the mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase (ERK) provides a means to perform highly detailed kinetic studies, assess heterogeneity between cells, and distinguish the subcellular localization of ERK activity. We describe here the methods needed to perform such measurements in a cell type of the investigator’s choosing. We discuss the selection of appropriate reporters and provide detailed methods for stably introducing reporters, collecting live-cell data, and automatically extracting quantitative information from individual cells.
- 21 July 2017
- Published by Springer Nature
- Vol. 1636, 35-59
Single-Cell Imaging of ERK Signaling Using Fluorescent Biosensors
Single-cell analysis of the mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase (ERK) provides a means to perform highly detailed kinetic studies, assess heterogeneity between cells, and distinguish the subcellular localization of ERK activity. We describe here the methods needed to perform such measurements in a cell type of the investigator’s choosing. We discuss the selection of appropriate reporters and provide detailed methods for stably introducing reporters, collecting live-cell data, and automatically extracting quantitative information from individual cells.
- 1 August 2011
- Published by Elsevier in Current Biology
- Vol. 21 (15) , R599-R609
Cell Division Orientation in Animals
- 1 August 2011
- Published by Elsevier in Current Biology
- Vol. 21 (15) , R599-R609
Cell Division Orientation in Animals